A new method for the determination of six compounds, chlorogenic acid, rutin, nicotiflorin, hederacoside C, hederasaponin B and ahederin, in ivy leaf extracts using high-performance liquid chromatography with diode array detector was developed. The chromatographic separation was performed on a YMC Hydrosphere C 18 analytical column using a gradient elution of 0.1% phosphoric acid and acetonitrile. The method was validated in terms of specificity, linearity (r 2 > 0.9999), precision [relative standard deviation (RSD) < 0.36%] and accuracy (97.4-103.8%). The limit of detection and limit of quantification were <20.32 and 61.56 ng for all analytes, respectively. The tested compounds were found to be stable in the ivy leaf extract from 0 to 48 h, and the RSD value for each compound was <0.90%. The validated method was successfully applied to quantify all six compounds in a 30% ethanol ivy leaf extract and 13 ivy leaf extract products. The results showed that all the tested products satisfied the minimum requirement for the content of hederacoside C. However, there were some differences between the contents of other constituents.
Introduction
Hedera helix L., commonly known as ivy or English ivy, belongs to a family called Araliaceae. Aqueous extraction of its juvenile leaves has been used since the nineteenth century in traditional medicine for the treatment of respiratory disorders because of its expectorant and bronchospasmolytic effects (1) . Today its use was standardized by a Commission monograph of the German regulatory authority since 1988, and various formulations of ivy leaf extract-containing medicinal products such as syrup, tablets, drops and suppositories are available (1, 2) . Those medicinal products can be used in common cold associated with cough and for the symptomatic treatment of acute and chronic inflammatory bronchial disorders (3) . A number of controlled clinical studies have demonstrated the efficacy and safety of ivy leaf extract-containing drugs in diverse populations and the respiratory diseases (1, 2, 4) . Owing to the experimental and empirical evidence on its efficacy and safety, there has been a significant increase of its prescription in many European countries including Germany (4) . In 2007, .80% of herbal expectorants prescribed in Germany comprised ivy leaf extract and amounted to nearly 2 million prescriptions nationwide and a volume of sales exceeding 13 million Euros (5) .
For its chemical constituents, triterpene saponins, flavonoids, polyacetylenes and some phenolic compounds have been isolated from H. helix (6, 7) . In particular, a-hederin, a triterpene saponin, has been revealed to be responsible for the therapeutic effect of ivy leaf extract because of its b 2 -adrenergic effects, which leads to the spasmolytic, bronchodilatory, mucolytic and expectorant action (1, 8) . Another triterpene saponin, hederacoside C, is known to be metabolized into the active form and produces the effect of a-hederin in the organism (8) . Thus, in the European Pharmacopoeia, a-hederin and hederacoside C should be detected in ivy leaf extract in the identification test using thin-layer chromatography (9) . In addition, an highperformance liquid chromatography (HPLC) test method for the quantitation of hederacoside C in ivy leaf extract is also described (9) . Ivy leaf extract is the top selling herbal medicine for cough, particularly for children, also in Korea. There are 62 ivy leaf extract pharmaceutical products as both prescribed and nonprescribed medication for the treatment of cough in Korea. The content of hederacoside C in the medicinal products containing ivy leaf extracts should be tested according to the HPLC method in Korean Pharmaceutical Codex (10) .
It has been widely accepted that the determination of one or two pharmacologically active constituents is not enough to characterize complex herbal extracts or herbal medicines. Although a-hederin and hederacoside C have been established as active constituents in ivy leaf extract or its medicinal products, the possibilities of other compounds' contributions to the efficacy or toxicity cannot be completely ruled out. However, until now, there have been only few studies reporting the analysis of chemical constituents of ivy leaf, whereas many studies have been conducted on the biological effects of a-hederin, hederacoside C and ivy leaf extract. An HPLC with diode array detector (HPLC-DAD) method was developed and validated to determine the content of a-hederin and hederacoside C in various ivy leaf extracts (11) . In another report, a-hederin, hederacoside C, hederagenin and oleandrine in the methanol extract of ivy leaf and some biological fluids were analyzed using LC-MS-MS (12) . Both studies were focused on the analysis of saponins in ivy leaf. On the other hand, Trute and Nahrstedt (13) quantified six main phenolics in ivy leaf extract using HPLC and capillary electrophoresis. Nevertheless, there has been no report on the simultaneous analysis of saponins and other types of compounds in ivy leaf.
In this study, we developed and validated an HPLC-DAD method for the simultaneous determination of saponins and other constituents, namely hederacoside C, hederasaponin B, a-hederin, chlorogenic acid, rutin and nicotiflorin (Figure 1 ), in ivy leaf extract. In addition, a 30% ethanol ivy leaf extract and 13 ivy leaf extract products were analyzed using the proposed method to compare not only the content of hederacoside C but also that of other compounds.
Experimental

Instrumentation and chromatographic conditions
The HPLC system consisted of an Agilent 1290 Infinity liquid chromatography system equipped with the G4220A Quad pump solvent delivery system and UV -Vis photodiode array detector G4212A (Agilent Technologies, Inc., Santa Clara, CA, USA). The output signal of the detector was recorded using Agilent ChemStation. Chromatographic separation was carried out on a YMC Hydrosphere C18 column (150 Â 4.6 mm i.d., 5 mm) equipped with an C18 guard column. The mobile phase was composed of acetonitrile (A) and 0.1% phosphoric acid (v/ v) (B) at a flow rate of 0.5 mL/min. Analysis was performed using a linear gradient program as follows: 0 min, 100% B and 75 min, 60% A and 40% B. Then, the column was reconditioned with 100% B for 5 min. The column temperature was set at 408C, and the analysis was monitored at 210 nm. Aliquots of 20 mL were injected into the HPLC.
Chemicals, reagents and materials Acetonitrile, methanol and water were of HPLC grade and purchased from Burdick & Jackson (Muskegon, MI, USA). HPLCgrade phosphoric acid was purchased from Sigma-Aldrich (St Louis, MO, USA). Nicotiflorin, hederacoside C, hederasaponin B, a-hederin and dried ivy leaves were provided by Central R&D Center, Ahngook Pharm and Elcomscience Co., Ltd. The compounds were isolated from the leaves of H. helix and identified by the comparison of their spectral data with those reported in the literature (14 -16) . The purity of all these compounds was .95.0%, as determined by the HPLC-DAD method with two wavelengths (210 and 260 nm). Chlorogenic acid and rutin were purchased from Sigma-Aldrich and Johnson Matthey Company (Seoul, Korea), respectively. Thirteen pharmaceutical products containing H. helix were purchased from a local pharmacy.
Standard solutions and sample preparation
The dried ivy leaves were cut into small pieces and extracted with 30% ethanol by the percolation method at 20 -308C for 4 -6 h and spray dried according to the method described in Korean Pharmacopoeia Codex. The dried ivy leaf 30% ethanol extracts were dissolved in 50% methanol at the concentration of 5 mg/mL, and the solution was filtered by a 0.2-mm nylon syringe Figure 1 . Structures of the six tested compounds in ivy leaf extract.
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filter (Thermo Scientific, Schwerte, Germany) before HPLC analysis.
Among the tested ivy leaf extract products, syrups (0.5 mL) were diluted by the same volume of 50% methanol (0.5 mL). Tablets were pulverized using a pestle and dissolved in 50% methanol at the concentration of 100 mg/mL. The solutions were extracted by ultrasonification using a Bransonic 5510 (Daubury, CT, USA) at 408C, and then centrifuged at 1,000 rpm for 5 min. The diluted syrups and the supernatants of the tablet extracts were filtered by a 0.2-mm nylon syringe filter (Thermo Scientific) before HPLC analysis.
Each stock standard solution of chlorogenic acid (1.47 mg/ mL), nicotiflorin (0.35 mg/mL), hederacoside C (9.835 mg/mL) and hederasaponin B (0.3985 mg/mL) was prepared in 50% methanol. The other two compounds, rutin (0.9 mg/mL) and a-hederin (0.568 mg/mL), were dissolved in methanol and prepared as stock standard solutions. The appropriate amount of every standard solution was mixed and diluted with methanol as indicated.
Validation procedure
The HPLC method was validated in terms of specificity, linearity, precision, accuracy and stability according to the International Conference on Harmonization guidelines. Specificity was determined by the calculation of peak purity facilitated by DAD and its corresponding computer software. Each retention time and UV spectrum was verified with those of each standard compound and spiking with authentic standards. To calculate calibration curves of the six compounds, standard solutions for each compound were prepared and diluted to the appropriate concentrations. Those solutions of six different concentrations of each compound were analyzed in triplicate. The calibration curves were then constructed by the peak areas at the corresponding amounts of each compound. The limit of detection (LOD) and limit of quantification (LOQ) were determined based on the signal-to-noise ratio (LOD ¼ 3.3 Â d/S, LOQ ¼ 10 Â d/S, where d is the standard deviation of the response and S is the slope of the calibration curve). Precision for the tested compounds was assayed at six different concentrations in duplicate on the same day. The precision of the developed method was expressed by the relative standard deviation (RSD). The accuracy of the method setup in this study was determined by the method of standard addition. The diluted sample solution of 30% ethanol extract of H. helix leaves (5 mg/mL) was spiked with the mixture of standard compounds in the ratios of 2 : 1, 1 : 1 and 2 : 3. Then, the resultant samples were analyzed by the proposed method and triplicate experiments were carried out. For comparison, an unspiked sample was concurrently prepared and analyzed simultaneously. For stability assay, samples were analyzed immediately after preparation and then reassayed after storage at the room temperature for 2, 4, 8, 12 and 24 h.
Results
Optimization of chromatographic conditions
The chromatographic conditions were optimized to obtain chromatograms with good resolution of adjacent peaks. 18 (150 Â 4.6 mm i.d., 5 mm) and YMC Hydrosphere C 18 (150 Â 4.6 mm i.d., 5 mm) columns, were applied to analyze the tested samples. The preferred chromatographic separation was achieved using a YMC Hydrosphere C 18 column. Various mixtures of water and acetonitrile in combination with several acids including phosphoric acid, acetic acid and boric acid were tested as a mobile phase to enhance the resolution and eliminate the peak tailing of the target compounds (17) . In our experimental conditions, the addition of 0.1% phosphoric acid in water increased the resolution of the peaks, whereas the addition of other acids resulted in unsatisfying resolution and peak broadening. Because saponins are generally have weak UV absorption or end absorption due to their lack of chromophore, evaporative light scattering detection (ELSD) was tested for the detection of three saponins, hederacoside C, hederasaponin B and a-hederin, and other compounds. Although there have been many successful application of ELSD for measuring saponins in various samples (18) , our application of ELSD could not quantitatively measure these compounds. Thus, the wavelength for detection was set at 210 nm, where all six compounds including three saponins could be measured by DAD. The presence of the six compounds was confirmed by comparing the retention times and UV spectra with those of each standard compound and spiking with authentic standards (Figure 2 ). The retention times of chlorogenic acid, rutin, nicotiflorin, hederacoside C, hederasaponin B and a-hederin were 23.16, 31.81, 34.52, 46.44, 52.49 and 67.14 min, respectively. In this chromatographic condition, resolution (R), asymmetry factor (T) and number of plates (N) were found to be satisfactory (Table I) .
Method validation
The developed HPLC-DAD method was validated for its selectivity, linearity, sensitivity, precision, accuracy and stability. The absorption spectrum of a single component remained invariable at each time point in one peak, which supported specificity of each peak. Calibration curves were linear in relatively wide range of amounts and all showed good linear regressions with high correlation coefficient values (r 2 . 0.9999) between the peak area and amount (Table II) . The LODs were between 2.03 and 20.32 ng, which showed a high sensitivity under this chromatographic condition. Precision was assayed at six concentrations on the same day. As listed in Table III , the RSDs of the assay were ,2.06%, which demonstrated a good precision of this method. To test the accuracy of the developed method, the diluted sample solution was spiked with the mixture of standard samples. The resultant samples were analyzed using the proposed method. The mean recovery of each compound was 95.08 -103.62% (Table III) . The stability of the tested compounds in sample solutions was evaluated for 24 h under ambient conditions. The content of each compound in the samples collected at the time points was not significantly different, and the RSD values were ,0.90% (Table IV) . The results indicated that the compounds and the sample were relatively stable for at least 24 h after preparation.
Analysis of ethanol extracts of ivy leaf and the medicinal products
The proposed HPLC-DAD method was applied to analyze the six compounds in a dried ivy leaf 30% ethanol extract (Table III) .
In our experimental conditions, the content of hederacoside C in the extract was 15.58%, which satisfied the specification, at least 10% of hederacoside C, required for dried ivy leaf 30% ethanol extract in Korean Pharmacopoeia Codex. Then, the established method was successfully applied to the analysis of 13 ivy products and showed good resolution separation of the tested compounds both in syrups and tablets (Figure 2 ). All the tested products, nine syrups and four tablets, satisfied the minimum requirement for the content of hederacoside C. Hederasaponin B was detected in none of the tested products. Among the tested products, syrups A -E and syrups F -H have the same specification for hederacoside C, 40 mg/100 mL and 70 mg/100 mL, respectively. However, there were some differences in the contents of other compounds even among the products with the same specification. In addition, products with similar content Resolutions were calculated between two neighboring peaks. of hederacoside C, syrups A and B, showed differences in the contents of other tested compounds. In line with this, tablets J and M, two products having similar content of hederacoside C, varied in the contents of other compounds. These results demonstrate the applicability of the newly developed method for the quality control of ivy leaf products. In addition, the similarity in the content of the specified compound does not ensure that there is no difference in the contents of other compounds (Table V) .
Discussion
Ivy leaf extract has been used for the treatment of various respiratory disorders and is the top selling herbal medicine for cough in many countries. It has been well known that ivy leaf extract has expectorant and bronchospasmolytic effect, and numerous studies have been conducted to reveal its mechanism of action, safety and pharmacological effect. Conventionally, ivy leaf extract and its medicinal products are standardized based on the content of hederacoside C. Because herbal medicines are comprised of complex chemicals, it is possible that other compounds as well as marker compounds can contribute to the safety and efficacy of herbal medicines. However, the studies on the analysis of its chemical constituents have been done less extensively. Several studies on the determination of chemical constituents in ivy leaf extract or its products have been mainly focused on the analysis of hederacoside C and other saponins. For example, Khdair et al. (19) determined the content of hederacoside C in ivythyme cough syrup using the HPLC-DAD method. In another study, the contents of hederacoside C and a-hederin in ivy leaves collected at different sites were determined by the HPLC-DAD method (11) . There is one report on the quantitation of six phenolic compounds in commercial ivy dry extract using the HPLC-DAD method (13) . In this study, the content of saponins including hederacoside C, an active constituent, was not determined and the method validation information was not provided. Thus, in this study, we tried to develop an analytical method that can determine various components, both saponins and other types of components, in ivy leaf extracts. HPLC conditions were optimized by adding phosphoric acid to water and detecting the compounds at UV 210 nm. This method showed acceptable results in all the validation factors tested. Compared with the previous studies (11, 19) , the run time was increased. However, it gave better resolution for not only the saponins such as hederacoside C and a-hederin but also other phenolic compounds with improved LOQ. The newly developed method was successfully applied to 13 different medicinal products containing ivy leaf extract. The results showed that all the tested products satisfied the minimum requirement for the content of hederacoside C. However, there were some differences in the content of other constituents within the products of the same specification. The differences were observed not only in the absolute value of hederacoside C, but also in the ratio of each compound to hederacoside C. Although there has been no direct evidence for the involvement of the tested compounds other than hederacoside C and a-hederin, the new method can be suggested as an improved quality control method by providing more information on the chemical constituents of ivy leaf extract and its medicinal product. Therefore, this method could be readily utilized for the quality control assessment of ivy leaf extracts and the related products.
Conclusion
In this study, a new method for the determination of six compounds, chlorogenic acid, rutin, nicotiflorin, hederacoside C, hederasaponin B and a-hederin, in ivy leaf extracts using HPLC-DAD was developed and validated in terms of specificity, linearity, precision, accuracy and stability. The validated method was successfully applied to quantify all six compounds in a 30% ethanol ivy leaf extract and 13 ivy leaf extract products. Compared with the conventional quality control method that measures the contents of hederacoside C in ivy leaf extracts, the newly developed method can provide more information about the chemical composition of ivy leaf extracts.
